Reducing early atrophy with leucine during immobilization of skeletal muscle
- Conditions
- Healthy young adults and elderly both male and female
- Registration Number
- NL-OMON23203
- Lead Sponsor
- Maastricht University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 48
Inclusion Criteria
Male or female age 18-35 or 60-80 years of age inclusive
- Healty, Moderatly active
Exclusion Criteria
- Previous participation in a 13C amino acid tracer study within the last 5 years
- Lower limb and/or back injuries
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The main study endpoint is cumulative FSR as a measure of muscle protein synthesis rates (MPS) based on the oral tracer deuterium oxide. In order to determine cumulative FSR, the following parameters will be measured via GC-C-IRMS and GCMS respectively:<br /><br>- Muscle protein-bound L-[2,3,3,3-2H4]-alanine enrichment (expressed as MPE)<br /><br>- Plasma free L-[2,3,3,3-2H4]-alanine enrichment (expressed as MPE)<br /><br>- Saliva 2H2O enrichment (Expressed as APE)<br /><br>- Fractional breakdown rates (FBR) of muscle protein based on 3,3-D2 phenylalanine tracer dilution in plasma and muscle free pool.<br /><br>- Fractional synthesis rates (FSR) of muscle protein based on L-[ring-13C6]-phenylalanine tracer incorporation into bound muscle protein.
- Secondary Outcome Measures
Name Time Method Quadriceps whole-muscle CSA as assessed via CT scan.<br /><br>- Plasma, muscle free, and muscle protein-bound L-[ring-13C6]-phenylalanine enrichment.<br /><br>- Activation of signaling molecules regulating muscle protein synthesis and breakdown will be established via Western blots. Quantitative Real-Time PCR Analysis of MAFbx/Atrogin-1, MuRF1, FoxO and Ubiquitin Expression will also be performed.